Alnylam Pharmaceuticals, Inc. (FRA:DUL)

Germany flag Germany · Delayed Price · Currency is EUR
285.30
-2.10 (-0.73%)
At close: Feb 20, 2026
Market Cap37.85B +10.6%
Revenue (ttm)3.16B +65.2%
Net Income267.22M
EPS1.98
Shares Outn/a
PE Ratio141.63
Forward PE33.60
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume4
Open287.10
Previous Close287.40
Day's Range285.30 - 290.00
52-Week Range198.70 - 423.00
Betan/a
RSI45.93
Earnings DateFeb 12, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2002
Employees 2,500
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol DUL
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements